Source:http://linkedlifedata.com/resource/pubmed/id/20507301
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
2010-7-20
|
| pubmed:abstractText |
The utility of ([18F])fluoro-2-deoxy- d-glucose positron-emission tomography (FDG-PET) for predicting outcome after autologous stem cell transplantation (ASCT) for diffuse large B cell lymphoma (DLBCL) is uncertain - existing studies include a range of histological subtypes or have a limited duration of follow-up. Thirty-nine patients with primary-refractory or relapsed DLBCL with pre-ASCT PET scans were analysed. The median follow-up was 3 years. The 3-year progression-free survival (PFS) for patients with positive PET scans pre-ASCT was 35% vs. 81% for those who had negative PET scans (P = 0.003). The overall survival (OS) in these groups was 39% and 81% (P = 0.01), respectively. In a multivariate analysis, PET result, number of salvage cycles and the presence of relapsed or refractory disease were shown to predict a longer PFS; PET negativity (P = 0.04) was predictive of a longer OS. PET is useful for defining those with an excellent prognosis post-ASCT. Although those with positive scans can still be salvaged with current treatments, PET may useful for selecting patients eligible for novel consolidation strategies after salvage therapies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jul
|
| pubmed:issn |
1365-2141
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
150
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
39-45
|
| pubmed:meshHeading |
pubmed-meshheading:20507301-Adolescent,
pubmed-meshheading:20507301-Adult,
pubmed-meshheading:20507301-Aged,
pubmed-meshheading:20507301-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20507301-Epidemiologic Methods,
pubmed-meshheading:20507301-Female,
pubmed-meshheading:20507301-Fluorodeoxyglucose F18,
pubmed-meshheading:20507301-Humans,
pubmed-meshheading:20507301-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:20507301-Male,
pubmed-meshheading:20507301-Middle Aged,
pubmed-meshheading:20507301-Patient Selection,
pubmed-meshheading:20507301-Peripheral Blood Stem Cell Transplantation,
pubmed-meshheading:20507301-Positron-Emission Tomography,
pubmed-meshheading:20507301-Prognosis,
pubmed-meshheading:20507301-Radiopharmaceuticals,
pubmed-meshheading:20507301-Recurrence,
pubmed-meshheading:20507301-Salvage Therapy,
pubmed-meshheading:20507301-Treatment Outcome,
pubmed-meshheading:20507301-Young Adult
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Improved survival for relapsed diffuse large B cell lymphoma is predicted by a negative pre-transplant FDG-PET scan following salvage chemotherapy.
|
| pubmed:affiliation |
Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia.
|
| pubmed:publicationType |
Journal Article,
Review,
Multicenter Study
|